ARCT — Arcturus Therapeutics Holdings Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1768224 ·
Last close
$7.97
Market Cap
$229.72M
52W High
$17.96
52W Low
$5.50
ADV30
654,974
Next earnings
2026-11-05
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 16,852,000 | — | -9,185,000 | -7,414,000 | 215,316,000 | 184,817,000 | 46,589,000 |
| Jun 2026 | 880,000 | — | -25,545,000 | -23,785,000 | 224,310,000 | 191,483,000 | 52,502,000 |
| Mar 2026 | 610,000 | — | -28,931,000 | -26,964,000 | 245,411,000 | 211,375,000 | 54,049,000 |
| Dec 2025 | 3,081,000 | — | -31,307,000 | -29,079,000 | 271,148,000 | 230,909,000 | 57,163,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-72,729,000
Investing CF
$-41,000
Financing CF
$12,929,000
CapEx
$-318,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-3.31
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$-565,339,000
Inventory
—
Receivables
$1,813,000
ST Investments
—
EBIT TTM
$-91,809,000
Pretax Income TTM
$-93,280,000
Interest Exp TTM
—
Analysts
10
Yahoo Snapshot (yfinance, live)
Total Revenue
$30,513,000
EBITDA
$-92,357,000
Free Cash Flow
$19,258,624
Enterprise Value
$127,998,352
Total Cash
$184,816,992
Total Debt
$18,244,000
Shares Out
28,822,514
Trailing EPS
$-3.10
Book Value
$5.93
ROE
-44.4%
ROA
-23.9%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 67,221,000 | -76,260,000 | -65,783,000 | 271,148,000 | 57,163,000 | 213,985,000 | -74,271,000 |
| Dec 2024 | 138,389,000 | -95,669,000 | -80,941,000 | 344,069,000 | 103,091,000 | 240,978,000 | -59,747,000 |
| Dec 2023 | 157,748,000 | -78,205,000 | -29,725,000 | 429,402,000 | 150,889,000 | 278,513,000 | -18,099,000 |
| Dec 2022 | 205,755,000 | 12,177,000 | 9,349,000 | 450,387,000 | 180,075,000 | 270,312,000 | 31,993,000 |
TTM Snapshot
Revenues TTM
$29,368,000
NetIncome TTM
$-93,276,000
OpCashFlow TTM
—
Assets (Latest)
$224,310,000
Forward EPS
$-3.41
Max Pain — expiry 2026-12-18
max pain strike: $12.50 · spot: $8.04 · call oi: 638 · put oi: 779
Expected Move to 2026-12-18:
±$3.38
(41.98%) —
implied range
$4.66 –
$11.41
· ATM straddle on $7.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| VNDA | Vanda Pharmaceuticals Inc. | $230.39M | $3.81 | — |
| FTH | Faeth Therapeutics, Inc. | $233.63M | $9.04 | — |
| BIOA | BioAge Labs, Inc. | $234.35M | $5.10 | — |
| IMRX | Immuneering Corp | $224.08M | $3.46 | — |
| RCKT | ROCKET PHARMACEUTICALS, INC. | $235.60M | $2.11 | — |
News headlines (Yahoo Finance, 1h cache)
Arcturus Therapeutics Announces $50 Million Investment by Meiji Seika Pharma as Part of Expanded Collaboration
2026-11-16 13:30 · Yahoo
What Arcturus Therapeutics (ARCT) Said on Its Q3 Earnings Call
2026-11-06 03:14 · Yahoo
Arcturus Therapeutics to Report Third Quarter Financial Results and Provide Corporate Update on November 5, 2026
2026-10-26 20:01 · Yahoo
Arcturus Highlights ARCT-810 Phase II Data, Unveils Next-Gen OTC Therapy Platform
2026-09-25 03:02 · Yahoo
Arcturus Therapeutics Announces Interim OTC Deficiency Phase 2 Results and Introduces LUNAR 2.0™ Next-Generation mRNA Delivery Platform
2026-09-23 20:01 · Yahoo
Arcturus Therapeutics to Present Ornithine Transcarbamylase (OTC) Deficiency Phase 2 Clinical Data and Provide Update on mRNA Liver Therapeutics Platform
2026-09-18 13:00 · Yahoo
Arcturus Therapeutics to Participate in Upcoming Investor Conferences
2026-08-31 20:01 · Yahoo
Arcturus Therapeutics (ARCT) Just Flashed Golden Cross Signal: Do You Buy?
2026-08-27 13:55 · Yahoo
Arcturus Therapeutics Eyes Phase III CF Call, OTC Data as Vaccine Funds Pipeline
2026-08-12 01:04 · Yahoo
Arcturus Therapeutics (ARCT) Reports Q3 Loss, Beats Revenue Estimates
2026-11-05 21:45 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.